Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my health be monitored throughout the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia clinical trial (NCT06696833). Contact the study team or your healthcare provider for specific answers.

What this study is about